How to register a medical device in Panama with MINSA (DNDM)

Sponsors keep mixing two Panama desks into one email: “we need MINSA for our device.” One desk is commercial registro sanitario. The other is clinical-research authorization. They are not the same petition, and swapping them mid-cycle is how a quarter disappears.

I am Julio Martinez-Clark, CEO of bioaccess®. This page answers the market-access question — how a medical device gets onto the Panamanian market under MINSA’s Dirección Nacional de Dispositivos Médicos (DNDM) — and how that file stays off the first-in-human critical path. It sits next to our LATAM market-access hub, the Importer of Record guide, and the Panama FIH device guide. Operator guidance only. Not a quote and not legal advice.

One-sentence answer

Commercial sale in Panama is a sanitary-registration file under Ley 90 of 26 December 2017 (as modified by Ley 92 of 12 September 2019) and Decreto Ejecutivo No. 490 of 4 October 2019, with DNDM as the classifying authority and a single Authorized Representative as the regulatory anchor. A MINSA/CNBI trial authorization is not a license to sell.

Two MINSA desks — write them on separate pages

Investigational use. Protocol review under Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C), with ethics at a CNBI-accredited Type II committee and RESEGIS registration before start. That path is for first-in-human and other clinical research. See the Decreto 21 explainer.

Commercial registro. Sale and distribution of a medical device that already has a clearance story elsewhere (often FDA or CE) follows Ley 90 / Ley 92 and Decreto 490. Risk class for registro sanitario follows current GHTF/IMDRF rules; DNDM classifies. The named Authorized Representative is the regulatory face of the product and, in Panama’s single-representative model, the importer-of-record anchor.

If your Gantt has one bar labeled “MINSA,” you do not have a plan. You have a hope.

What the single Authorized Representative model means

Panama is a single-representative market. The representative on the registro is the sanitary face of the device. Changing that name is closer to a new market entry than a contract amendment — the same pattern we describe for other single-AAR Central American markets on the independent registration-holder strategy page.

Design implication for US and European manufacturers: do not put the commercial distributor on the certificate if you want the option to change channel later. Hold titularidad with an entity that answers to the manufacturer’s transfer doctrine — then authorize distributors underneath that holder.

What belongs in the commercial dossier (operator list)

Exact forms and annexes move with DNDM practice. The working stack sponsors assemble before translators start is stable:

• Device identification, intended use, and GHTF/IMDRF risk class as DNDM will see it
• Manufacturer and manufacturing sites, with quality-system evidence appropriate to class
• Technical file / essential-requirements evidence already used for FDA or CE, mapped to the Panamanian petition — not dumped as a zip of US folders
• Labels and IFU in Spanish for the configuration you will sell
• Authorized Representative appointment and local entity documentation
• Tecnovigilancia ownership under the holder, not under whichever distributor won the first tender

Electrical/EMC or RF homologation for wireless devices, when required, runs through Panama’s telecom authority as a separate vendor track. Do not bury that inside the sanitary clock.

What this file is not

• It is not a substitute for Decreto 21 ethics + MINSA research review when you still need human data.
• It is not an investigational import permit. Trial units enter under the research authorization; commercial units enter under registro.
• It is not a free pass to use a Panama FIH as proof of market clearance. First patient in and registro sanitario are different end states.

How bioaccess® runs the Panama holder seat

On the live market-access offer, bioaccess® acts as the Panamanian Authorized Representative through our own local entity for sanitary registration, importer-of-record duties, sworn translations, government fees, and tecnovigilancia as holder. Pricing for the LATAM Launch Subscription is published on bioaccessla.com/market-access (USD 7,500 per year per country for the first device family; additional families at the published add-on rates). Timelines are confirmed at proposal against the current DNDM queue — we do not invent a statutory day-count here.

Operator checklist before you open a Panama registro folder

1. Write “trial” and “registro” on two pages. Put owners and statutes on each page.
2. Decide the Authorized Representative before you pick a distributor.
3. Confirm the configuration you will sell matches the labels and IFU you will file — not the investigational configuration from an FIH.
4. Map FDA/CE evidence to the DNDM petition; do not ship the US zip as the dossier.
5. Budget tecnovigilancia and holder change cost as part of channel design, not as a later surprise.

Talk with bioaccess® when you need Panama registro held independent of the commercial channel — or when you are sequencing a Panama FIH under Decreto 21 into a later DNDM market file without mixing the desks.